Zimmer and Biomet provide updates following the 2nd in a series of "Integration Summits" where company leadership is fleshing out the details of their $13 billion merger.
Leadership at Zimmer (NYSE:ZMH) and Biomet have been on merger overdrive in recent weeks, holding summits and hosting presentations as the companies navigate the tricky business of a $13 billion merger.
Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range
Here's a look at some of the top regulatory stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; Japan probes Biomet-Zimmer merger; Allergan caves to shareholder meeting after Valeant, Ackman rally support; Remote monitoring companies join forces for cardiac patients
A 2nd suitor for orthopedic device maker Biomet ceded the field early to Zimmer, regulatory filings show, but Biomet held out for better terms from its cross-town rival.
Japanese regulators are the latest to probe the pending merger of Biomet and Zimmer to make sure it meets anti-trust muster.
Biomet settles a portion of a patent infringement lawsuit brought by an affiliate of patent troll Acacia Research Group and loses a European case brought over some of its bone cements.
Biomet said this week that it settled a portion of a patent infringement case with a notorious patent troll and lost a trade secrets theft lawsuit brought in Germany over some of its bone cements.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany